Foster R S, Foster J C, Costanza M C
Arch Surg. 1984 Oct;119(10):1138-40. doi: 10.1001/archsurg.1984.01390220024005.
Numerous reports have demonstrated that blood transfusions given prior to renal allografting have an immunomodulating effect that leads to increased graft survival. To determine if blood transfusions would adversely affect the outcome for patients with breast cancer, we examined 226 patients with invasive breast cancer who had a mastectomy and found 65 (29%) had received transfusions. The patients who had transfusions and those who did not were similar in age, clinical tumor-node-metastasis stage, and number of histologic nodal metastases. At a median follow-up of 52 months for surviving patients, 48 (21%) of the patients were dead. Log-rank and Cox regression analyses that compared patients who had transfusions v those who did not showed no excess of either overall deaths or deaths due to cancer in the group that received transfusions. The hypothesis that blood transfusions might have an adverse effect on survival was not supported by this study. Additional studies involving other groups of patients with malignant neoplasms and other blood donor populations are needed.
众多报告表明，肾移植前输血具有免疫调节作用，可提高移植肾的存活率。为了确定输血是否会对乳腺癌患者的预后产生不利影响，我们对226例行乳房切除术的浸润性乳腺癌患者进行了检查，发现65例（29%）接受过输血。接受输血和未接受输血的患者在年龄、临床肿瘤-淋巴结-转移分期以及组织学淋巴结转移数量方面相似。对存活患者进行的中位随访时间为52个月，48例（21%）患者死亡。对数秩检验和Cox回归分析比较了接受输血和未接受输血的患者，结果显示接受输血组的总死亡人数或癌症死亡人数均无增加。本研究不支持输血可能对生存产生不利影响这一假设。需要开展涉及其他恶性肿瘤患者群体和其他献血人群的进一步研究。
